Search

Your search keyword '"Georgios A Maragkos"' showing total 2 results
Start Over Author "Georgios A Maragkos" Publisher american society of neuroradiology (asnr)
2 results on '"Georgios A Maragkos"'

1. Initial Stroke Thrombectomy Experience in New York City during the COVID-19 Pandemic

Author

J Mocco, Kurt A. Yaeger, Trevor Hardigan, Tomoyoshi Shigematsu, Johanna T Fifi, Shahram Majidi, Travis R. Ladner, Georgios A Maragkos, B. Yim, C. Rossitto, and Jacques Lara-Reyna

Subjects
Adult, Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, MEDLINE, 030218 nuclear medicine & medical imaging, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, Occlusion, Pandemic, Health care, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Pandemics, Stroke, Aged, Retrospective Studies, Thrombectomy, Aged, 80 and over, Interventional, SARS-CoV-2, business.industry, Incidence (epidemiology), COVID-19, Retrospective cohort study, Middle Aged, medicine.disease, Treatment Outcome, Reperfusion, Emergency medicine, Female, New York City, Neurology (clinical), Coronavirus Infections, business, 030217 neurology & neurosurgery
Abstract

New York City has become the global epicenter of the coronavirus 2019 (COVID-19) pandemic. Despite a massive shift in health care resources, cerebrovascular disease continues to be a substantial burden. We review the first 10 patients undergoing thrombectomy following a series of governmental and institutional policy changes diverting resources to the care of critically ill patients with COVID-19. Ten patients with emergent large-vessel occlusion underwent thrombectomy between March 23 and April 1, 2020. Five patients tested positive for the COVID-19 virus. Successful reperfusion was achieved in 9 of 10 patients, at a median time of 37 minutes from vascular access. The postprocedural NIHSS score improved by an average of 7.7 points. Of the 5 patients positive for COVID-19, none have experienced a critical respiratory illness. We report the early incidence of COVID-19 positivity in patients with emergent large-vessel occlusion and demonstrate that thrombectomy continues to be an efficacious option, as well as safe for health care providers.

Published
2020
Full Text
View/download PDF

2. Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms

Author

M. Litao, R. W. Crowley, Andrew F. Ducruet, Bradley A. Gross, Peter Kan, Christopher S. Ogilvy, Stephen R. Chen, Clemens M. Schirmer, Keaton Piper, Omar Tanweer, Maxim Mokin, Howard A. Riina, Justin R Mascitelli, Jeremiah N. Johnson, C. McDougall, Ajith J. Thomas, A. Enriquez-Marulanda, Jan-Karl Burkhardt, Adib A. Abla, C Griessenauer, Benjamin K Hendricks, Vivek J. Srinivasan, Felipe C. Albuquerque, Louis J. Kim, Georgios A Maragkos, Lee A Birnbaum, Aditya Srivatsan, Michael R. Levitt, Shamsher S. Dalal, Ethan A. Winkler, and Brian T Jankowitz

Subjects
Adult, Male, medicine.medical_specialty, Subarachnoid hemorrhage, medicine.medical_treatment, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Aneurysm, Blood vessel prosthesis, Atlas (anatomy), Product Surveillance, Postmarketing, medicine, Humans, Radiology, Nuclear Medicine and imaging, cardiovascular diseases, Embolization, Aged, Retrospective Studies, Coil embolization, Interventional, business.industry, Stent, Intracranial Aneurysm, Retrospective cohort study, Middle Aged, medicine.disease, Embolization, Therapeutic, Blood Vessel Prosthesis, Treatment Outcome, medicine.anatomical_structure, cardiovascular system, Female, Stents, Neurology (clinical), Radiology, business, 030217 neurology & neurosurgery
Abstract

BACKGROUND AND PURPOSE: The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. MATERIALS AND METHODS: On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up. RESULTS: Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results